Shots:

• Barhemsys is the first and only antiemetic to be approved for the rescue treatment of PONV in patients who have failed standard prophylaxis with its anticipated launch in H2’20
• The results of the clinical program showed that Barhemsys (10mg) is significantly more effective compare to PBO (42% vs 29%) while in another study Barhemsys (5mg) + other antiemetics vs PBO demonstrated improvement in protection from PONV (58% vs 47%)
• Barhemsys is an IV formulation of the selective dopamine D2 and D3 antagonist amisulpride (2.5 mg/mL). Additionally- Acacia’s Byfavo (remimazolam injection) is currently under FDA’s review for use in procedural sedation in adult with its anticipated PDUFA as Apr 05-2020

Click here to read full press release/ article | Ref: Acaia | Image: Twitter